Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer. Second-generation antiandrogens approved by the FDA for the treatment of patients with prostate cancer include abiraterone acetate (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa).
Dreicer is associate director for Clinical Research and deputy director of the University of Virginia Cancer Center; section head of Medical Oncology and co-director of the Paul Mellon Urologic Institute; and professor of Medicine and Urology at the University of Virginia School of Medicine.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.